<DOC>
	<DOCNO>NCT02179775</DOCNO>
	<brief_summary>The purpose study determine whether Quince Oxymel effective prevention Migraine attack patient simultaneous upper gastrointestinal dysfunction .</brief_summary>
	<brief_title>Effect `` Sekanjabin e Safarjali '' ( Quince Oxymel ) Prevention Migraine Attacks</brief_title>
	<detailed_description>This randomize , placebo-controlled , triple blind clinical study evaluate effect oral use `` Sekanjebin e Safarjali '' ( Quince Oxymel ) Prevention Migraine attack patient simultaneous upper gastrointestinal dysfunction.45 patient Migraine headache age 15-70 , take sign informed consent , accord International headache society criterion headache [ 2 ] include trial . 45 case Migraine headache simultaneous upper gastrointestinal dysfunction allocate three arm use simple randomization . Quince Oxymel , propranolol placebo give encode , innominate bottle shape color . Quince oxymel placebo prescribe 10 cc , three time day 4 week . Frequency , duration intensity Migraine Attacks begin time 4 week trial , evaluate , primary outcome measure .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Stomach Diseases</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>minimum age 18 year old give write informed consent least 2 migraine attack per month patient older 70 year old patient Diabetes mellitus patient chronic obstructive pulmonary disease asthma pregnancy severe depression patient affect sexual disorder bradyarrhythmic patient positive history hypersensitivity reaction quince , ginger , propranolol naproxen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>